Amanote Research
Register
Sign In
Selumetinib Increases the Efficacy of First-Line Dacarbazine
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-rw2013-129
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
June 13, 2013
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
A Phase I Dose-Escalation Study of Selumetinib in Combination With Docetaxel or Dacarbazine in Patients With Advanced Solid Tumors
BMC Cancer
Cancer Research
Oncology
Genetics
Efficacy of Canakinumab as First-Line Biologic Agent in Adult-Onset Still’s Disease
Arthritis Research & Therapy
A Randomised Phase II Trial of Selumetinib vs Selumetinib Plus Temsirolimus for Soft-Tissue Sarcomas
British Journal of Cancer
Cancer Research
Oncology
PCN20 Comparative Efficacy and Economic Evaluation of Dacarbazine and Temozolomide in Treatment of Malignant Melanoma in Iran
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
The Efficacy and Safety of First-Line Therapies for Preventing Chronic Post-Surgical Pain: A Network Meta-Analysis
Oncotarget
Oncology
Assessing the Tolerability and Efficacy of First-Line Chemotherapy in Elderly Patients With Metastatic HER2−ve Breast Cancer
ecancermedicalscience
Cancer Research
Oncology
Efficacy of Potassium-Competitive Acid Blocker vs Proton Pump Inhibitor as First-Line and Second-Line Treatment for Helicobacter Pylori Eradication
Open Journal of Gastroenterology and Hepatology
An International Comparison of the Efficacy, Cost and Myelotoxicity of First-Line Therapy for Advanced Follicular Non-Hodgkin Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
First Line of Dementia Prevention
Health Evaluation and Promotion
